PhaseRx makes more noise than silence with mRNA delivery

January 31, 2017 Christoph Graener

Having ditched RNA silencing in 2012, PhaseRx president and CEO Dr. Robert Overell explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how delivering messenger RNA inside diseased cells may revolutionize and grow the current USD 4 billion enzyme replacement market.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Robert Overell – CEO, PhaseRx

Previous Article
ProNAI defects from oligos to DDR as Sierra Oncology

Sierra Oncology president and CEO Dr. Nick Glover explains how the company is rebranding itself from its fo...

Next Article
Double-barreled approach doubles survival times in recurrent glioma patients

Marty Duvall, newly-appointed CEO of San Diego-based gene therapy technology company Tocagen, explains how ...